New ultrasound dye could spot hidden heart defects
NCT ID NCT06938347
First seen Jun 25, 2026 · Last updated Jul 07, 2026 · Updated 4 times
Summary
This phase 3 trial tests a new contrast agent called ASI-02 against the standard agitated saline for detecting right-to-left shunts in the heart. About 300 adults with suspected shunts will receive both agents during an echocardiogram. The goal is to see if ASI-02 finds shunts more accurately and safely than the current method.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ASI-02 (a contrast agent for ultrasound)
- What this could lead to
- If successful, ASI-02 could become a more reliable and consistent contrast agent for detecting heart defects that allow blood to bypass the lungs.
- What could go wrong
- This is a phase 3 trial, but the primary goal is diagnostic accuracy, not treatment. Even if ASI-02 works better than saline, it may not change patient outcomes or be widely adopted.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Nov 2025
- Expected to finish
-
Sep 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient is clinically indicated for a saline contrast TTE study with a suspected right-to-left shunt 2. Patient must be at least 18 years of age inclusive, at the time of signing the informed consent 3. Able to communicate effectively with trial personnel Exclusion Criteria: 1. Female patients who are pregnant or lactating. All women of child-bearing potential (WOCBP) must have a negative urine pregnancy test at screening regardless of contraceptive use history 2. WOCBP are excluded unless they have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to ASI-02 dose administration 3. Allergy to polysorbate 80 (PS-80) 4. American Society of Anesthesiologists (ASA) physical status classification IV, V, or VI, except that participants with ASA physical status IV due solely to recent suspected transient ischemic attack or cerebrovascular accident are eligible for inclusion 5. Current illness or pathology that in the opinion of the investigator would prevent undergoing investigational product administration due to a significant safety risk to the patient 6. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg) 7. Unstable cardiovascular status defined as: 1. myocardial infarction or unstable angina pectoris within 6 months prior to procedure day 2. symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease 3. clinically significant congenital heart defects (excluding an atrial septal defect \[ASD\], patent foramen ovale \[PFO\], or pulmonary arteriovenous malformation \[PAVM\]) 4. current uncontrolled cardiac arrhythmias causing clinical symptoms requiring medical intervention or hemodynamic compromise 5. acute pulmonary embolus or pulmonary infarction 6. acute myocarditis or pericarditis 7. acute aortic dissection 8. untreated atrial fibrillation 8. Any major surgery within 30 days prior to screening 9. Participation in any investigational drug, device, or placebo study within 30 days prior to screening 10. Vulnerable adult participant populations (e.g., incarcerated or cognitively challenged adults)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Right-to-left shunt are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
8 sites in 2 countries. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
AH Illinois Masonic Center
RECRUITINGChicago, Illinois, 60657, United States
-
Aurora St. Lukes Medical Center
RECRUITINGMilwaukee, Wisconsin, 53215, United States
-
CentraCare
RECRUITINGSaint Cloud, Minnesota, 56303, United States
-
Jackson Heart Clinic
RECRUITINGJackson, Mississippi, 39216, United States
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
-
Toronto General
RECRUITINGToronto, M5G 2C4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.